EB
Emergent BioSolutions Inc.
EBS · NYSE
$6.34 -0.55% (-$0.04)
1M +1.61%
Market Cap $337.2M
P/E Ratio -
Div. Yield -
ROE 35.91%
Bulios Fair Price
$7.67
21.1% upside
Current Price
$6.34
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EBS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
100 /100
Cheap P/S 0.44x
P/FCF 3.93x
P/B 0.99x
Growth
0 /100
Declining Rev. growth 12.72%
Book val. growth 27.79%
EPS growth N/A
Profitability
41 /100
Moderate Gross margin 49.40%
FCF margin 11.15%
Net margin 22.96%
Quality
9 /100
Poor ROIC 6.87%
Asset turnover 0.69x
ROE 35.91%
Debt
36 /100
Moderate Debt/Equity 1.70x
Int. coverage -1.87x
Current ratio 5.42x
Stability
25 /100
Unstable Beta 2.34x
Profitable years 1
Rev. volatility 14.98%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EBS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Joseph C. Papa Jr.
Employees
900
Headquarters
Gaithersburg
Upcoming events
04 NOV
Earnings
Upcoming earnings report